Differentiated Thyroid Cancer (DTC) Recruiting Phase 3 Trials for Cabozantinib (DB08875)

Also known as: Differentiated Thyroid Cancer

IndicationStatusPhase
DBCOND0062237 (Differentiated Thyroid Cancer (DTC))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03690388A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted TherapyTreatment